{
  "company": "Exact Sciences",
  "ticker": "EXAS",
  "period": {
    "from": "2026-03-16",
    "to": "2026-04-15",
    "days": 30
  },
  "sentiment_breakdown": {
    "positive": 25,
    "negative": 33,
    "neutral": 41
  },
  "synthesis": {
    "executive_summary": "Sentiment analysis for Exact Sciences (EXAS) from 2026-03-16 to 2026-04-15. Analyzed 99 items across FDA and news sources.",
    "key_findings": [],
    "overall_sentiment": "neutral"
  },
  "top_positive": [
    {
      "title": "What to know about Cologuard Classic in Tucson on PGA Tour Champions",
      "date": "2026-03-16",
      "source": "news",
      "score": 0.778
    },
    {
      "title": "Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies.",
      "date": "2026 May 1",
      "source": "pubmed",
      "score": 0.713
    },
    {
      "title": "Oncology Precision Medicine Market Trends and Investment Opportunities 2026-2030 - Advancements in CAR-T and Gene Therapies Propel Precision Oncology Growth",
      "date": "2026-03-27",
      "source": "news",
      "score": 0.637
    },
    {
      "title": "Learning to breathe for radiation therapy: A scoping review of deep inspiration breath-hold training.",
      "date": "2026 Apr 2",
      "source": "pubmed",
      "score": 0.527
    },
    {
      "title": "Everpure Aligns FlashBlade//EXA with NVIDIA AI Factory Architectures, Previews Data Stream",
      "date": "2026-03-16",
      "source": "news",
      "score": 0.494
    },
    {
      "title": "Select Health Care Portfolio's Exact Sciences Corp(EXAS) Holding History",
      "date": "2026-04-02",
      "source": "alpha_vantage",
      "score": 0.494
    },
    {
      "title": "Health care again among the state’s biggest M&A deals of the past year",
      "date": "2026-03-18",
      "source": "alpha_vantage",
      "score": 0.494
    },
    {
      "title": "Exact Sciences (EXAS) merger with Abbott moving forward after shareholder approval",
      "date": "2026-03-17",
      "source": "alpha_vantage",
      "score": 0.477
    },
    {
      "title": "First-principles investigation and device simulation of TlPbI3-based perovskite solar cells with machine learning-driven efficiency prediction",
      "date": "2026-04-06",
      "source": "news",
      "score": 0.46
    },
    {
      "title": "Exact Sciences Corp. stock faces analyst scrutiny amid moderate buy consensus and growth challenges",
      "date": "2026-03-23",
      "source": "alpha_vantage",
      "score": 0.44
    }
  ],
  "top_negative": [
    {
      "title": "Katie Couric said she follows 3 tips to prevent colon cancer after her husband died of the disease",
      "date": "2026-04-13",
      "source": "news",
      "score": -0.958
    },
    {
      "title": "Preclinical circulating tumor DNA shedding duration and prognostic implications of modeling 3669 patients with cancer in the American Cancer Society Cancer Prevention Study-3 and Circulating Cell-Free Genome Atlas Substudy 3.",
      "date": "2026 Apr 1",
      "source": "pubmed",
      "score": -0.95
    },
    {
      "title": "Colorectal Cancer Advocates Urge Congress to Fund New Research",
      "date": "2026-03-27",
      "source": "news",
      "score": -0.945
    },
    {
      "title": "Companion Diagnostics Market Size is Projected to Hit USD 26.38 Billion by 2035 – SNS Insider",
      "date": "2026-04-13",
      "source": "news",
      "score": -0.869
    },
    {
      "title": "Global Noninvasive Cancer Diagnostics Market to Reach $165.2 Billion by 2030 as Liquid Biopsy, AI-Enabled Screening and Multi-Cancer Detection Tests Transform Oncology",
      "date": "2026-04-09",
      "source": "news",
      "score": -0.823
    },
    {
      "title": "Soccer legend Abby Wambach said colon cancer screening at 35 likely saved her life",
      "date": "2026-03-22",
      "source": "news",
      "score": -0.791
    },
    {
      "title": "CREB5 regulates stem cell-like transcriptional programs to enhance tumor progression in prostate cancer.",
      "date": "2026 Mar 1",
      "source": "pubmed",
      "score": -0.791
    },
    {
      "title": "Rational adjustment of dose to reduce adverse reactions (RADAR) in patients with platinum-sensitive recurrent ovarian cancer: Results from the phase II NEWTON trial (ENGOT-ov49).",
      "date": "2026 Mar 2",
      "source": "pubmed",
      "score": -0.784
    },
    {
      "title": "Colorectal Cancer and Mortality Risk Among Older Adults With vs Without Adenoma on Prior Colonoscopy.",
      "date": "2026 Apr 9",
      "source": "pubmed",
      "score": -0.758
    },
    {
      "title": "Exact Sciences Corp. stock (US30063P1057): Why cancer screening leadership now drives investor focus",
      "date": "2026-04-14",
      "source": "alpha_vantage",
      "score": -0.66
    }
  ],
  "raw_data": {
    "total_items": 99,
    "items": [
      {
        "source": "news",
        "source_name": "Business Insider",
        "title": "Katie Couric said she follows 3 tips to prevent colon cancer after her husband died of the disease",
        "description": "Katie Couric's husband died of colon cancer at 42. It prompted her to make three major changes to reduce her risk with diet, exercise, and screening.",
        "url": "https://www.businessinsider.com/colon-cancer-katie-couric-rules-to-reduce-risk-2026-4",
        "date": "2026-04-13",
        "published_at": "2026-04-13T18:08:40Z",
        "sentiment": {
          "label": "negative",
          "score": -0.958,
          "confidence": 0.96
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Companion Diagnostics Market Size is Projected to Hit USD 26.38 Billion by 2035 – SNS Insider",
        "description": "Precision Medicine Revolution and Rising Cancer Prevalence Drive 11.9% CAGR as Healthcare Shifts Toward Targeted Therapies. Precision Medicine Revolution and Rising Cancer Prevalence Drive 11.9% CAGR as Healthcare Shifts Toward Targeted Therapies.",
        "url": "https://www.globenewswire.com/news-release/2026/04/13/3272705/0/en/Companion-Diagnostics-Market-Size-is-Projected-to-Hit-USD-26-38-Billion-by-2035-SNS-Insider.html",
        "date": "2026-04-13",
        "published_at": "2026-04-13T15:30:00Z",
        "sentiment": {
          "label": "negative",
          "score": -0.869,
          "confidence": 0.87
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Global Noninvasive Cancer Diagnostics Market to Reach $165.2 Billion by 2030 as Liquid Biopsy, AI-Enabled Screening and Multi-Cancer Detection Tests Transform Oncology",
        "description": "Market growth is driven by rising cancer prevalence, demand for minimally invasive procedures, and advances in precision diagnostics....",
        "url": "https://www.globenewswire.com/news-release/2026/04/09/3271135/0/en/Global-Noninvasive-Cancer-Diagnostics-Market-to-Reach-165-2-Billion-by-2030-as-Liquid-Biopsy-AI-Enabled-Screening-and-Multi-Cancer-Detection-Tests-Transform-Oncology.html",
        "date": "2026-04-09",
        "published_at": "2026-04-09T14:12:00Z",
        "sentiment": {
          "label": "negative",
          "score": -0.823,
          "confidence": 0.82
        }
      },
      {
        "source": "news",
        "source_name": "Royal Society of Chemistry",
        "title": "First-principles investigation and device simulation of TlPbI3-based perovskite solar cells with machine learning-driven efficiency prediction",
        "description": "RSC Adv., 2026, 16,18022-18060DOI: 10.1039/D6RA01288D, Paper Open Access &nbsp This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence.Md. Harun-Or-Rashid, Hanane Etabti, Md. Tauki Tazwar, Md Amzad Sadik Abid, Md Farha…",
        "url": "https://pubs.rsc.org/en/content/articlelanding/2026/ra/d6ra01288d",
        "date": "2026-04-06",
        "published_at": "2026-04-06T23:00:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.46,
          "confidence": 0.46
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Molecular Diagnostics Market Size is Expected to Reach USD 43.50 Billion by 2035 Owing to the Surging Demand for Accurate and Early Disease Detection Globally | SNS Insider",
        "description": "Molecular diagnostics market to grow from $18.26 Bn to $43.50 Bn by 2035, driven by PCR, NGS, and demand for early, precise diagnosis....",
        "url": "https://www.globenewswire.com/news-release/2026/04/03/3267957/0/en/Molecular-Diagnostics-Market-Size-is-Expected-to-Reach-USD-43-50-Billion-by-2035-Owing-to-the-Surging-Demand-for-Accurate-and-Early-Disease-Detection-Globally-SNS-Insider.html",
        "date": "2026-04-03",
        "published_at": "2026-04-03T09:00:00Z",
        "sentiment": {
          "label": "negative",
          "score": -0.226,
          "confidence": 0.23
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Minerva Announces Leadership Transition",
        "description": "Jim O’Connor joins as Chief Business Officer and General Counsel Jim O’Connor joins as Chief Business Officer and General Counsel",
        "url": "https://www.globenewswire.com/news-release/2026/04/02/3267830/32445/en/Minerva-Announces-Leadership-Transition.html",
        "date": "2026-04-02",
        "published_at": "2026-04-02T20:05:00Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "news",
        "source_name": "Barchart.com",
        "title": "Buy the Dip: These 3 Over-$100 Stocks Just Hit New 52-Week Lows",
        "description": "Among the 128 new 52-week lows on the NYSE on Tuesday, there were five with share prices of $100 or higher. Not all of them are worth buying on the dip. We...",
        "url": "https://www.barchart.com/story/news/1097982/buy-the-dip-these-3-over-100-stocks-just-hit-new-52-week-lows",
        "date": "2026-04-01",
        "published_at": "2026-04-01T18:51:21Z",
        "sentiment": {
          "label": "positive",
          "score": 0.128,
          "confidence": 0.13
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Oncology Biomarkers Market Trends and Investment Opportunities Report 2026-2030: Global, Regional and Country-Level Outlook",
        "description": "Rising demand for personalized oncology therapies, AI-driven biomarker discovery, expanding precision diagnostics, and liquid biopsy tech Rising demand for personalized oncology therapies, AI-driven biomarker discovery, expanding precision diagnostics, and li…",
        "url": "https://www.globenewswire.com/news-release/2026/03/30/3264368/28124/en/Oncology-Biomarkers-Market-Trends-and-Investment-Opportunities-Report-2026-2030-Global-Regional-and-Country-Level-Outlook.html",
        "date": "2026-03-30",
        "published_at": "2026-03-30T08:58:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.153,
          "confidence": 0.15
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Colorectal Cancer Advocates Urge Congress to Fund New Research",
        "description": "With Young Lives at Stake, More Than 250 Colorectal Cancer Advocates Demand Action With Young Lives at Stake, More Than 250 Colorectal Cancer Advocates Demand Action",
        "url": "https://www.globenewswire.com/news-release/2026/03/27/3263970/0/en/Colorectal-Cancer-Advocates-Urge-Congress-to-Fund-New-Research.html",
        "date": "2026-03-27",
        "published_at": "2026-03-27T16:31:00Z",
        "sentiment": {
          "label": "negative",
          "score": -0.945,
          "confidence": 0.95
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Oncology Precision Medicine Market Trends and Investment Opportunities 2026-2030 - Advancements in CAR-T and Gene Therapies Propel Precision Oncology Growth",
        "description": "Dublin, March  27, 2026  (GLOBE NEWSWIRE) -- The \"Oncology Precision Medicine Market Report 2026\" has been added to  ResearchAndMarkets.com's offering.    ...",
        "url": "https://www.globenewswire.com/news-release/2026/03/27/3263857/28124/en/Oncology-Precision-Medicine-Market-Trends-and-Investment-Opportunities-2026-2030-Advancements-in-CAR-T-and-Gene-Therapies-Propel-Precision-Oncology-Growth.html",
        "date": "2026-03-27",
        "published_at": "2026-03-27T14:44:00Z",
        "sentiment": {
          "label": "positive",
          "score": 0.637,
          "confidence": 0.64
        }
      },
      {
        "source": "news",
        "source_name": "Yahoo Entertainment",
        "title": "Abbott Laboratories (ABT) Announces Completion of Acquisition of Exact Sciences",
        "description": "",
        "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_2499cb75-2e4c-4c25-bfe4-bcceedada92f",
        "date": "2026-03-26",
        "published_at": "2026-03-26T15:50:39Z",
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "news",
        "source_name": "Yahoo Entertainment",
        "title": "\"More Than Golf\": John Molner Reflects on the 2026 Cologuard Classic",
        "description": "While it looks like a traditional tournament on the surface, its purpose runs much deeper.",
        "url": "https://sports.yahoo.com/articles/more-golf-john-molner-reflects-204119878.html",
        "date": "2026-03-24",
        "published_at": "2026-03-24T20:41:19Z",
        "sentiment": {
          "label": "positive",
          "score": 0.361,
          "confidence": 0.36
        }
      },
      {
        "source": "news",
        "source_name": "Royal Society of Chemistry",
        "title": "Water-extractable organic matter from tropical soils and biochar amendment tailors the colloidal behavior of nanoparticles and mitigates their toxicity through molecular eco-corona formation",
        "description": "Environ. Sci.: Nano, 2026, Advance ArticleDOI: 10.1039/D5EN01164G, PaperLaís G. Fregolente, João Vitor dos Santos, Gabriela H. Da Silva, Theodoro da R. Salles, Simone G. S. dos Santos, Luelc S. Costa, Gabriela A. Nogueira, Márcia C. Bisinoti, Carlos A. Pérez,…",
        "url": "https://pubs.rsc.org/en/content/articlelanding/2026/en/d5en01164g",
        "date": "2026-03-23",
        "published_at": "2026-03-23T00:00:00Z",
        "sentiment": {
          "label": "neutral",
          "score": 0.026,
          "confidence": 0.03
        }
      },
      {
        "source": "news",
        "source_name": "Business Insider",
        "title": "Soccer legend Abby Wambach said colon cancer screening at 35 likely saved her life",
        "description": "Olympic gold medalist Abby Wambach had a colonoscopy in her 30s after a family history of colon cancer. It found polyps that may have become tumors.",
        "url": "https://www.businessinsider.com/abby-wambach-colonoscopy-35-likely-saved-her-life-2026-3",
        "date": "2026-03-22",
        "published_at": "2026-03-22T13:57:46Z",
        "sentiment": {
          "label": "negative",
          "score": -0.791,
          "confidence": 0.79
        }
      },
      {
        "source": "news",
        "source_name": "GlobeNewswire",
        "title": "Predictive Biomarkers Market to Reach USD 156.85 Billion by 2035; Rising Adoption of Precision Medicine and Targeted Therapies Driving Market Growth – SNS Insider",
        "description": "Rising Chronic Disease Burden, AI-Driven Biomarker Discovery, and Expanding Companion Diagnostics Pipelines Fuel Unprecedented Market Expansion. Rising Chronic Disease Burden, AI-Driven Biomarker Discovery, and Expanding Companion Diagnostics Pipelines Fuel U…",
        "url": "https://www.globenewswire.com/news-release/2026/03/17/3257053/0/en/Predictive-Biomarkers-Market-to-Reach-USD-156-85-Billion-by-2035-Rising-Adoption-of-Precision-Medicine-and-Targeted-Therapies-Driving-Market-Growth-SNS-Insider.html",
        "date": "2026-03-17",
        "published_at": "2026-03-17T11:45:00Z",
        "sentiment": {
          "label": "negative",
          "score": -0.477,
          "confidence": 0.48
        }
      },
      {
        "source": "news",
        "source_name": "The Times of India",
        "title": "Who is Ali Larijani, ‘Kennedy of Iran’ and Iran’s top security chief, allegedly killed by Israel",
        "description": "Israel has claimed it killed Iran’s top security official Ali Larijani in recent airstrikes, a move that could reshape Tehran’s power structure. A long-time strategist and influential conservative leader, Larijani came from a powerful political dynasty once l…",
        "url": "https://economictimes.indiatimes.com/news/defence/who-is-ali-larijani-kennedy-of-iran-and-irans-top-security-chief-allegedly-killed-by-israel/articleshow/129630467.cms",
        "date": "2026-03-17",
        "published_at": "2026-03-17T10:43:20Z",
        "sentiment": {
          "label": "positive",
          "score": 0.273,
          "confidence": 0.27
        }
      },
      {
        "source": "news",
        "source_name": "The Times of India",
        "title": "Who is Ali Larijani, ‘Kennedy of Iran’ and Iran’s top security chief, allegedly killed by Israel",
        "description": "Israel has claimed it killed Iran’s top security official Ali Larijani in recent airstrikes, a move that could reshape Tehran’s power structure. A long-time strategist and influential conservative leader, Larijani came from a powerful political dynasty once l…",
        "url": "https://economictimes.indiatimes.com/news/new-updates/who-is-ali-larijani-kennedy-of-iran-and-irans-top-security-chief-allegedly-killed-by-israel/articleshow/129630467.cms",
        "date": "2026-03-17",
        "published_at": "2026-03-17T10:43:20Z",
        "sentiment": {
          "label": "positive",
          "score": 0.273,
          "confidence": 0.27
        }
      },
      {
        "source": "news",
        "source_name": "Storagereview.com",
        "title": "Everpure Aligns FlashBlade//EXA with NVIDIA AI Factory Architectures, Previews Data Stream",
        "description": "Everpure is aligning its FlashBlade//EXA platform with NVIDIA’s evolving AI Factory architectures while previewing a new automation layer called Everpure Data Stream. The announcement extends Evergreen//One support to EXA and introduces a service designed to …",
        "url": "https://www.storagereview.com/news/everpure-aligns-flashblade-exa-with-nvidia-ai-factory-architectures-previews-data-stream",
        "date": "2026-03-16",
        "published_at": "2026-03-16T20:30:04Z",
        "sentiment": {
          "label": "positive",
          "score": 0.494,
          "confidence": 0.49
        }
      },
      {
        "source": "news",
        "source_name": "USA Today",
        "title": "What to know about Cologuard Classic in Tucson on PGA Tour Champions",
        "description": "The PGA Tour Champions is back at it this week with the Cologuard Classic. Here's what you need to know ahead of the tournament in Tucson, Arizona.",
        "url": "https://golfweek.usatoday.com/story/sports/golf/champions/2026/03/16/cologuard-classic-2026-pga-tour-champions-la-paloma-preview/89121653007/",
        "date": "2026-03-16",
        "published_at": "2026-03-16T16:30:35Z",
        "sentiment": {
          "label": "positive",
          "score": 0.778,
          "confidence": 0.78
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences Corp. stock (US30063P1057): Why cancer screening leadership now drives investor focus",
        "url": "https://www.ad-hoc-news.de/boerse/ueberblick/exact-sciences-corp-stock-us30063p1057-why-cancer-screening-leadership/69144294",
        "date": "2026-04-14",
        "summary": "Exact Sciences Corp. is a leader in non-invasive cancer screening, particularly with its flagship product Cologuard for colorectal cancer. The company's focus on early detection, expanding into multi-cancer screening, and strong market penetration in the U.S. and other English-speaking markets make it a compelling investment. Analysts view Exact Sciences favorably due to its growth potential, reimbursement stability, and strategic partnerships, despite risks like competition and regulatory chang",
        "sentiment_score": 0.436889,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences Corp. stock (US30063P1057): Why cancer screening leadership now drives investor focus",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/exact-sciences-corp-stock-us30063p1057-why-cancer-screening-leadership/69144294",
        "date": "2026-04-14",
        "summary": "Exact Sciences Corp. is a leader in non-invasive cancer screening, with its flagship product Cologuard revolutionizing colorectal cancer detection. The company's expansion into multi-cancer detection and strategic partnerships position it for continued growth in the diagnostics sector. Investors in the United States and English-speaking markets are focusing on Exact Sciences due to its potential in preventive diagnostics and strong market positioning.",
        "sentiment_score": 0.464749,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences Corp. stock (US30063P1057): Is its cancer screening push strong enough for U.S. inves",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/exact-sciences-corp-stock-us30063p1057-is-its-cancer-screening-push/69120611",
        "date": "2026-04-10",
        "summary": "Exact Sciences Corp., listed on Nasdaq under EXAS, is a leader in non-invasive cancer screening with products like Cologuard and the Oncotype DX portfolio. The company's strategy focuses on molecular diagnostics, recurring revenue streams from return testing, and expanding into multi-cancer detection, aligning with growing U.S. healthcare demands for early detection. While analysts see it as a growth leader, potential risks include reimbursement cuts, competition from other blood tests, and oper",
        "sentiment_score": 0.03433,
        "sentiment_label": "Neutral",
        "relevance_score": 0.330904,
        "sentiment": {
          "label": "negative",
          "score": -0.273,
          "confidence": 0.27
        }
      },
      {
        "source": "alpha_vantage",
        "title": "EXAS Technical Analysis & Stock Price Forecast",
        "url": "https://intellectia.ai/en/stock/EXAS/technical",
        "date": "2026-04-04",
        "summary": "The article provides a technical analysis for Exact Sciences Corp (EXAS), indicating a \"Strong Buy\" overall consensus based on aggregated technical signals. It details various indicators like RSI, MACD, and moving averages, along with key support and resistance levels. Despite some sell signals from momentum oscillators like RSI and Stochastic, the stock is trading above its key moving averages, suggesting a bullish trend.",
        "sentiment_score": 0.542687,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences Corp. stock: Acquired by Abbott – What it means for you now",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/exact-sciences-corp-stock-acquired-by-abbott-what-it-means-for-you/69067597",
        "date": "2026-04-03",
        "summary": "Abbott Laboratories recently acquired Exact Sciences for $23 billion, integrating its cancer screening products like Cologuard and Oncotype DX into Abbott's diagnostics portfolio. This acquisition positions North American investors to gain exposure to the $60 billion U.S. cancer screening market through a diversified healthcare giant. The deal is expected to contribute $3 billion in incremental revenue to Abbott in 2026, despite an initial EPS dilution, and analysts generally view it positively ",
        "sentiment_score": 0.436227,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences Corp. stock: Acquired by Abbott – What it means for you now",
        "url": "https://www.ad-hoc-news.de/boerse/ueberblick/exact-sciences-corp-stock-acquired-by-abbott-what-it-means-for-you/69067597",
        "date": "2026-04-03",
        "summary": "Abbott Laboratories completed its $23 billion acquisition of Exact Sciences on March 23, 2026, integrating Exact Sciences' cancer screening products like Cologuard and Oncotype DX into Abbott's diagnostics division. This acquisition positions Abbott in the growing $60 billion U.S. cancer screening market, offering North American investors exposure to diversified revenue and reduced single-product risk. Analysts view the deal positively, expecting it to be accretive long-term despite near-term EP",
        "sentiment_score": 0.000626,
        "sentiment_label": "Neutral",
        "relevance_score": 0.333747,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences Stock: Is The Post-Earnings Slide A Buying Setup for 2026?",
        "url": "https://www.ad-hoc-news.de/boerse/ueberblick/exact-sciences-stock-is-the-post-earnings-slide-a-buying-setup-for-2026/68632891",
        "date": "2026-04-03",
        "summary": "Exact Sciences stock has seen a post-earnings slide, but the company's core Cologuard franchise continues to grow, and profitability is becoming clearer. The article examines the fundamental changes, Wall Street's sentiment, and how US investors might position themselves for 2026. It highlights the company's strong revenue growth, improving margins, and robust cash position, despite ongoing unprofitability on a GAAP basis, making it a risk-reward test for high-growth healthcare investors.",
        "sentiment_score": 0.297772,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Select Health Care Portfolio's Exact Sciences Corp(EXAS) Holding History",
        "url": "https://www.gurufocus.com/guru-portfolio/Select%20Health%20Care%20Portfolio/EXAS",
        "date": "2026-04-02",
        "summary": "This article from GuruFocus.com, titled \"Select Health Care Portfolio's Exact Sciences Corp(EXAS) Holding History,\" provides historical holding information for Exact Sciences Corp (EXAS) within the Select Health Care Portfolio. The content is primarily a navigation-heavy page from a financial data website, indicating where users can find such data and related investment tools. It does not provide direct analysis or details of the holding history itself, but rather signposts the availability of s",
        "sentiment_score": 0.031358,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.494,
          "confidence": 0.49
        }
      },
      {
        "source": "alpha_vantage",
        "title": "EXACT Sciences Corp. Experiences Revision in Stock Evaluation Amid Mixed Market Signals",
        "url": "https://www.marketsmojo.com/news/stocks-in-action/exact-sciences-corps-technical-trend-changes-from-bullish-to-mildly-bullish-amid-mixed-indicators-3925987",
        "date": "2026-03-30",
        "summary": "EXACT Sciences Corp., a Pharmaceuticals & Biotechnology company, has received a mixed stock evaluation with varying technical indicators. Despite this, the company has significantly outperformed the S&P 500 over both the past year and decade, demonstrating strong resilience and stock performance recovery. Key technical indicators show both bullish and bearish signals across different timeframes.",
        "sentiment_score": 0.260452,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Vanguard disaggregates holdings; Exact Sciences (NASDAQ: EXAS) shows 0 shares",
        "url": "https://www.stocktitan.net/sec-filings/EXAS/schedule-13g-a-exact-sciences-corp-amended-passive-investment-disclos-eeadd5078360.html",
        "date": "2026-03-27",
        "summary": "The Vanguard Group has reported 0 shares of Exact Sciences (NASDAQ: EXAS) common stock, representing 0% ownership, following an internal realignment on January 12, 2026. This change means certain Vanguard subsidiaries will now report their ownership separately, in accordance with SEC Release No. 34-39538. The filing emphasizes that this reclassification is a reporting change, not an indication of a sale.",
        "sentiment_score": 0.040548,
        "sentiment_label": "Neutral",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences Corp. stock faces renewed scrutiny amid biotech sector volatility and pipeline update",
        "url": "https://www.ad-hoc-news.de/boerse/ueberblick/exact-sciences-corp-stock-faces-renewed-scrutiny-amid-biotech-sector/68988789",
        "date": "2026-03-26",
        "summary": "Exact Sciences Corp. (EXAS) is under renewed scrutiny due to biotech sector volatility and internal developments, despite its leadership in cancer screening with Cologuard. The company, which generated $3.25 billion in revenue last year, faces challenges from competition and reimbursement pressures but is pursuing growth through advancements in multi-cancer detection tests. US investors are monitoring EXAS for its potential in early detection markets and its stable financial health, though risks",
        "sentiment_score": 0.259893,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences Corp. stock faces renewed scrutiny amid biotech sector volatility and pipeline update",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/exact-sciences-corp-stock-faces-renewed-scrutiny-amid-biotech-sector/68988789",
        "date": "2026-03-26",
        "summary": "Exact Sciences Corp. (EXAS) is under renewed scrutiny due to biotech sector volatility and internal developments, despite its leading position in cancer screening diagnostics with products like Cologuard. Investors are closely watching its ability to navigate reimbursement challenges and advance its pipeline, especially in multi-cancer early detection tests. The company's strong capital structure and focus on growth in the preventive healthcare market make it a key player for US investors seekin",
        "sentiment_score": 0.006207,
        "sentiment_label": "Neutral",
        "relevance_score": 0.301372,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Key facts: Abbott Buys Exact Sciences; Notes Settle $105; Nasdaq Delist",
        "url": "https://www.tradingview.com/news/tradingview:063a6549e37bf:0-key-facts-abbott-buys-exact-sciences-notes-settle-105-nasdaq-delist/",
        "date": "2026-03-23",
        "summary": "Exact Sciences has amended the terms for its convertible notes, with conversions now cash-settled at $105.00 per share, effective March 23, 2026. Following Abbott Laboratories' acquisition of Exact Sciences, the company completed its merger, requested Nasdaq delisting, and plans to suspend SEC reporting.",
        "sentiment_score": -0.407881,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Abbott completes Exact Sciences acquisition",
        "url": "https://www.massdevice.com/abbott-completes-exact-sciences-acquisition/",
        "date": "2026-03-23",
        "summary": "Abbott has finalized its acquisition of cancer diagnostics developer Exact Sciences for $21 million, following a November 2025 agreement. This acquisition positions Abbott as a leader in cancer screening and diagnostics, integrating Exact Sciences' products like Cologuard, Oncotype Dx, Cancerguard, and Oncodetect. The deal is projected to add approximately $3 billion in incremental sales for Abbott in 2026.",
        "sentiment_score": 0.417936,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences Corp (EXAS) Files 8-K Announcing Material Agreements, Amendments, and Supplemental Indentures – March 2026",
        "url": "https://www.minichart.com.sg/2026/03/23/exact-sciences-corp-exas-files-8-k-announcing-material-agreements-amendments-and-supplemental-indentures-march-2026/",
        "date": "2026-03-23",
        "summary": "Exact Sciences Corporation (EXAS) has completed its acquisition by Abbott Laboratories on March 23, 2026, as announced in an 8-K filing. Consequently, Exact Sciences is now a wholly-owned subsidiary of Abbott, and its common stock has been halted from trading and will be delisted from Nasdaq. Shareholders will receive the specified merger consideration, and the company will cease its SEC reporting obligations as an independent entity.",
        "sentiment_score": 0.035582,
        "sentiment_label": "Neutral",
        "relevance_score": 0.34939,
        "sentiment": {
          "label": "positive",
          "score": 0.273,
          "confidence": 0.27
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Abbott Acquires Exact Sciences, Strengthening Leadership in Cancer Screening",
        "url": "https://intellectia.ai/news/stock/abbott-acquires-exact-sciences-strengthening-leadership-in-cancer-screening",
        "date": "2026-03-23",
        "summary": "Abbott has completed its acquisition of Exact Sciences on March 20, 2026, positioning itself as a leader in the rapidly expanding cancer screening and diagnostics market, projected to be a $60 billion industry in the U.S. This strategic move adds market-leading products like Cologuard® and Oncotype DX® to Abbott's portfolio, enhancing its offerings for early cancer detection and personalized treatment. The acquisition is expected to boost Abbott's growth, strengthen its competitive edge, and dri",
        "sentiment_score": 0.029729,
        "sentiment_label": "Neutral",
        "relevance_score": 0.327771,
        "sentiment": {
          "label": "negative",
          "score": -0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences Announced Transfer or Voluntary Withdrawal of Listing",
        "url": "https://www.tradingview.com/news/tradingview:9f617a00194da:0-exact-sciences-announced-transfer-or-voluntary-withdrawal-of-listing/",
        "date": "2026-03-23",
        "summary": "Exact Sciences (EXAS) announced that its merger has been completed and, as a result, informed Nasdaq of its request to delist and deregister its common stock. Trading of EXAS stock was halted before the market open on March 23, 2026, and the company plans to file Form 15 to suspend SEC reporting obligations. This announcement follows an SEC filing dated March 23, 2026.",
        "sentiment_score": -0.622284,
        "sentiment_label": "Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.026,
          "confidence": 0.03
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences Corp. stock faces analyst scrutiny amid moderate buy consensus and growth challenges",
        "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/exact-sciences-corp-stock-faces-analyst-scrutiny-amid-moderate-buy/68964225",
        "date": "2026-03-23",
        "summary": "Exact Sciences Corp. (ISIN: US30063P1057) is currently facing analyst scrutiny, maintaining a \"Moderate Buy\" consensus from 24 analysts with an average price target of $69.90. The stock, trading around $64.64 USD on NASDAQ, is supported by its Cologuard and Oncotype DX portfolios, driving revenue growth in cancer screening. The company is actively pursuing expansion into European markets, which is attracting interest from DACH region investors due to rising healthcare spending in Germany and Swi",
        "sentiment_score": 0.496536,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.44,
          "confidence": 0.44
        }
      },
      {
        "source": "alpha_vantage",
        "title": "The Bull Case For Exact Sciences (EXAS) Could Change Following Walgreens’ Nationwide Cologuard Pharmacy Rollout",
        "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-exas/exact-sciences/news/the-bull-case-for-exact-sciences-exas-could-change-following",
        "date": "2026-03-21",
        "summary": "Walgreens has partnered with Exact Sciences for a nationwide rollout of the Cologuard colorectal cancer screening test through its pharmacies, which could significantly impact Exact Sciences' growth. While this expansion addresses care gaps and diversifies screening access, investors should also consider Exact Sciences' historical cash burn and dependence on Cologuard, despite new data on its Oncodetect and Cancerguard tests. The company's investment narrative projects substantial revenue and ea",
        "sentiment_score": 0.317906,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences (NASDAQ: EXAS) secures approvals as Abbott merger targets March 23 close",
        "url": "https://www.stocktitan.net/sec-filings/EXAS/8-k-exact-sciences-corp-reports-material-event-84457867e21f.html",
        "date": "2026-03-21",
        "summary": "Exact Sciences has announced that all regulatory approvals and clearances for its merger with Abbott Laboratories have been obtained. Stockholders previously approved the transaction on February 20, 2026, and the merger is now anticipated to close on March 23, 2026, subject to the satisfaction or waiver of remaining conditions. Exact Sciences will become a wholly-owned subsidiary of Abbott upon completion of the merger.",
        "sentiment_score": 0.279511,
        "sentiment_label": "Somewhat-Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.318,
          "confidence": 0.32
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Abbott to close $21B Exact Sciences acquisition Monday",
        "url": "https://www.medtechdive.com/news/abbott-to-close-21b-exact-sciences-acquisition-monday/815315/",
        "date": "2026-03-20",
        "summary": "Abbott is set to finalize its $21 billion acquisition of Exact Sciences on Monday, having received all necessary regulatory clearances. This strategic move is expected to significantly bolster Abbott's presence in cancer screening and diagnostics, adding a new platform and an estimated $3 billion in incremental sales by 2026. Exact Sciences is known for its Cologuard test and other molecular cancer detection technologies, which Abbott anticipates will help reach millions more people for early ca",
        "sentiment_score": 0.490846,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.2,
          "confidence": 0.2
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences to be acquired by Abbott after receiving all regulatory approvals; closing anticipated March 23, 2026",
        "url": "https://www.tradingview.com/news/tradingview:a22546d93f58a:0-exact-sciences-to-be-acquired-by-abbott-after-receiving-all-regulatory-approvals-closing-anticipated-march-23-2026/",
        "date": "2026-03-20",
        "summary": "Exact Sciences announced that all regulatory approvals for its merger with Abbott have been received, with the transaction expected to close on March 23, 2026. This merger will make Exact Sciences a direct, wholly owned subsidiary of Abbott, following shareholder approval and regulatory clearance obtained on March 19, 2026. The closing is subject to remaining conditions and customary risks.",
        "sentiment_score": 0.405868,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Health care again among the state’s biggest M&A deals of the past year",
        "url": "https://biztimes.com/health-care-again-among-the-states-biggest-ma-deals-of-the-past-year/?amp=1",
        "date": "2026-03-18",
        "summary": "For the third consecutive year, a healthcare-focused company deal is among Wisconsin's largest mergers and acquisitions. Exact Sciences, based in Madison, was acquired by Illinois-based Abbott Laboratories for $21 billion in November. This acquisition follows other significant healthcare M&A deals in the state and notable acquisitions by Modine and several other Wisconsin-based companies across various sectors.",
        "sentiment_score": 0.411627,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.494,
          "confidence": 0.49
        }
      },
      {
        "source": "alpha_vantage",
        "title": "EXACT Sciences Corp. Hits New 52-Week High at $104.00",
        "url": "https://www.marketsmojo.com/news/stocks-in-action/exact-sciences-corp-hits-new-52-week-high-at-10400-3899129",
        "date": "2026-03-18",
        "summary": "EXACT Sciences Corp. (EXAS) has achieved a new 52-week high of $104.00, marking a significant 142.34% appreciation over the past year, far outpacing the S&P 500. The company, a mid-cap player in pharmaceuticals and biotechnology with a market capitalization of $19.8 billion, shows a manageable debt-to-equity ratio despite being a loss-making entity with a negative return on equity. This price movement highlights strong investor sentiment and dynamic market activity for the stock.",
        "sentiment_score": 0.497128,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026",
        "url": "https://www.businesswire.com/news/home/20260317158639/en/Exact-Sciences-to-Present-New-Molecular-Residual-Disease-and-Multi-Cancer-Early-Detection-Data-at-AACR-2026",
        "date": "2026-03-17",
        "summary": "Exact Sciences Corp. announced it will present new data on molecular residual disease (MRD) testing and multi-cancer early detection (MCED) at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The presentations will highlight findings from the Oncodetect® test in triple-negative breast cancer and updated performance for the Cancerguard® test, reinforcing the company's strategy to detect cancer earlier and monitor disease post-treatment. These results showcase advancements ",
        "sentiment_score": 0.436268,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "EXACT Sciences Corp. Hits New 52-Week High at $103.92",
        "url": "https://www.marketsmojo.com/news/stocks-in-action/exact-sciences-corp-hits-new-52-week-high-at-10392-3897175",
        "date": "2026-03-17",
        "summary": "EXACT Sciences Corp. reached a new 52-week high of $103.92, demonstrating strong performance in the Pharmaceuticals & Biotechnology sector with a 142.13% stock price increase over the last year. Despite being a loss-making entity, the company maintains a manageable debt-to-equity ratio of 0.58 and a market capitalization of approximately $19.74 billion, with investors focusing on capital appreciation due to no dividend yield.",
        "sentiment_score": 0.408462,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Exact Sciences (EXAS) merger with Abbott moving forward after shareholder approval",
        "url": "https://www.msn.com/en-us/money/markets/exact-sciences-exas-merger-with-abbott-moving-forward-after-shareholder-approval/ar-AA1Xe0H5?ocid=TobArticle&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1",
        "date": "2026-03-17",
        "summary": "This article reports on the merger between Exact Sciences (EXAS) and Abbott (ABT) moving forward after Exact Sciences shareholders approved the deal. The acquisition will allow Exact Sciences to expand its cancer diagnostic products into new markets and leverage Abbott's global presence. The approval marks a significant step towards the completion of the merger.",
        "sentiment_score": 0.460601,
        "sentiment_label": "Bullish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.477,
          "confidence": 0.48
        }
      },
      {
        "source": "alpha_vantage",
        "title": "Jain Global LLC Purchases Shares of 481,607 Exact Sciences Corporation $EXAS",
        "url": "https://www.marketbeat.com/instant-alerts/filing-jain-global-llc-purchases-shares-of-481607-exact-sciences-corporation-exas-2026-03-16/",
        "date": "2026-03-16",
        "summary": "Jain Global LLC has acquired a significant new position in Exact Sciences (NASDAQ:EXAS), purchasing 481,607 shares valued at approximately $26.35 million. Other institutional investors like Holocene Advisors and Fred Alger Management also increased their stakes, bringing total institutional ownership to about 88.82%. Despite the increased institutional interest, analysts maintain a cautious outlook, with an average \"Reduce\" rating and a consensus target price of $92.13, even as the stock trades ",
        "sentiment_score": -0.24687,
        "sentiment_label": "Somewhat-Bearish",
        "relevance_score": 1.0,
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "pubmed",
        "pmid": "41981308",
        "title": "Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial.",
        "authors": "Mahalingam D et al.",
        "journal": "Nature medicine",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41981308/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41981246",
        "title": "Interpretable multiple instance learning for hematologic diagnosis from peripheral blood smears.",
        "authors": "Singi S et al.",
        "journal": "Communications medicine",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41981246/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41980102",
        "title": "A plasma-based DNA test for quantification of disease burden in acute myeloid leukemia patients undergoing bone marrow transplantation.",
        "authors": "Wang Y et al.",
        "journal": "Proceedings of the National Academy of Sciences of the United States of America",
        "date": "2026 Apr 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41980102/",
        "sentiment": {
          "label": "negative",
          "score": -0.44,
          "confidence": 0.44
        }
      },
      {
        "source": "pubmed",
        "pmid": "41979444",
        "title": "Interference-Limited Absorption in Dense Molecular Nanolayers Near Reflecting Surfaces.",
        "authors": "Zhou Z et al.",
        "journal": "The journal of physical chemistry letters",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41979444/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41977584",
        "title": "Effect of Inorganic Salts on Synthesis of Poly(glycidyl methacrylate) Microspheres, Their Functionalization with Poly(ethyleneimine) and Evaluation of Its Use for Removal of Acid Red 27, Acetaminophen and Nitrites.",
        "authors": "Martínez JM et al.",
        "journal": "Polymers",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41977584/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41974879",
        "title": "Synergistic multiscale reinforcement of sand concrete incorporating steel fibers and granulated blast-furnace slag.",
        "authors": "Hafsi H et al.",
        "journal": "Scientific reports",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41974879/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41974150",
        "title": "Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.",
        "authors": "Colombo N et al.",
        "journal": "Lancet (London, England)",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41974150/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41974026",
        "title": "Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies.",
        "authors": "Gordon SC et al.",
        "journal": "Hepatology communications",
        "date": "2026 May 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41974026/",
        "sentiment": {
          "label": "positive",
          "score": 0.713,
          "confidence": 0.71
        }
      },
      {
        "source": "pubmed",
        "pmid": "41972831",
        "title": "Multi-target stool DNA test adherence among individuals screened for colorectal cancer through the US Defense Health Agency.",
        "authors": "Gohil S et al.",
        "journal": "Current medical research and opinion",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41972831/",
        "sentiment": {
          "label": "negative",
          "score": -0.599,
          "confidence": 0.6
        }
      },
      {
        "source": "pubmed",
        "pmid": "41968859",
        "title": "Protective Role of Atriplex halimus L. Against Sodium Benzoate-Induced Fat Benzene Accumulation, Bone Marrow and Liver Alterations in Wistar Rats.",
        "authors": "Zeghib K et al.",
        "journal": "Current drug metabolism",
        "date": "2026 Apr 8",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41968859/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41968177",
        "title": "Built-in thiol mesoporous carbon immunosensor to detect carcinoembryonic antigen in human serum.",
        "authors": "Echeverri D et al.",
        "journal": "Mikrochimica acta",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41968177/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41966557",
        "title": "Characterization of real-world clinical and pathological differences between HER2-0 and HER2-low localized breast cancer.",
        "authors": "Hollmén M et al.",
        "journal": "Cancer treatment and research communications",
        "date": "2026 Apr 7",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41966557/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41965791",
        "title": "PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registry.",
        "authors": "Hörner M et al.",
        "journal": "NPJ breast cancer",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41965791/",
        "sentiment": {
          "label": "negative",
          "score": -0.128,
          "confidence": 0.13
        }
      },
      {
        "source": "pubmed",
        "pmid": "41965218",
        "title": "Optimization of methylated DNA markers to rule out endometrial cancer in patients with abnormal uterine bleeding.",
        "authors": "Bakkum-Gamez JN et al.",
        "journal": "Gynecologic oncology",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41965218/",
        "sentiment": {
          "label": "negative",
          "score": -0.421,
          "confidence": 0.42
        }
      },
      {
        "source": "pubmed",
        "pmid": "41964702",
        "title": "Influence of water quality on the composition and distribution of riparian vegetation in the Cheliff River, Algeria.",
        "authors": "Bouzada N et al.",
        "journal": "Environmental monitoring and assessment",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41964702/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41963505",
        "title": "The role of the molecular tumor board: learnings from the ROME trial.",
        "authors": "Marchetti P et al.",
        "journal": "NPJ precision oncology",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41963505/",
        "sentiment": {
          "label": "negative",
          "score": -0.382,
          "confidence": 0.38
        }
      },
      {
        "source": "pubmed",
        "pmid": "41962306",
        "title": "Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial.",
        "authors": "Curigliano G et al.",
        "journal": "ESMO open",
        "date": "2026 Apr 9",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41962306/",
        "sentiment": {
          "label": "negative",
          "score": -0.202,
          "confidence": 0.2
        }
      },
      {
        "source": "pubmed",
        "pmid": "41961224",
        "title": "BRCA1/2 Reversion Mutations in Japanese Patients with Metastatic Breast Cancer Progressing on Olaparib: OLIVE (WJOG15321B).",
        "authors": "Sakai H et al.",
        "journal": "Breast cancer (Tokyo, Japan)",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41961224/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41960911",
        "title": "Investigating the distribution of antibiotic resistance genes in relation to bacterial, fungal, and functional diversity in a hay field.",
        "authors": "de Santana CO et al.",
        "journal": "Microbiology spectrum",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41960911/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41958399",
        "title": "Chronic inorganic arsenic exposure impairs locomotor performance and socio-affective behavior in zebrafish.",
        "authors": "Ionescu C et al.",
        "journal": "Biomolecules & biomedicine",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41958399/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41958279",
        "title": "Neutrophil reactive oxygen species response to Trichomonas vaginalis modulated by palmitic acid.",
        "authors": "Sepúlveda-Angulo J et al.",
        "journal": "Parasites, hosts and diseases",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41958279/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41955827",
        "title": "Feasibility of quality indicators to assess the prevalence of guideline adherence in a german cohort of patients with advanced or metastatic breast cancer: Results of the BRE-BY-MED study.",
        "authors": "Brandstetter LS et al.",
        "journal": "Cancer treatment and research communications",
        "date": "2026 Apr 3",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41955827/",
        "sentiment": {
          "label": "negative",
          "score": -0.527,
          "confidence": 0.53
        }
      },
      {
        "source": "pubmed",
        "pmid": "41955197",
        "title": "Inhibition of Chikungunya virus nsP2 protease in vitro by scorpion venom peptide pantinin-1.",
        "authors": "Mastalipour M et al.",
        "journal": "PloS one",
        "date": "2026-04-15",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41955197/",
        "sentiment": {
          "label": "negative",
          "score": -0.361,
          "confidence": 0.36
        }
      },
      {
        "source": "pubmed",
        "pmid": "41954995",
        "title": "CREB5 regulates stem cell-like transcriptional programs to enhance tumor progression in prostate cancer.",
        "authors": "Makovec A et al.",
        "journal": "Oncotarget",
        "date": "2026 Mar 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41954995/",
        "sentiment": {
          "label": "negative",
          "score": -0.791,
          "confidence": 0.79
        }
      },
      {
        "source": "pubmed",
        "pmid": "41954938",
        "title": "Survival and Treatment Patterns in Stage III Inflammatory and Noninflammatory Breast Cancer.",
        "authors": "Leone JP et al.",
        "journal": "JAMA network open",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41954938/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41954928",
        "title": "Colorectal Cancer and Mortality Risk Among Older Adults With vs Without Adenoma on Prior Colonoscopy.",
        "authors": "Gupta S et al.",
        "journal": "JAMA",
        "date": "2026 Apr 9",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41954928/",
        "sentiment": {
          "label": "negative",
          "score": -0.758,
          "confidence": 0.76
        }
      },
      {
        "source": "pubmed",
        "pmid": "41954264",
        "title": "The use of skin explants in Brazil: A scoping review of applications, methodologies and research trends.",
        "authors": "Marchesim H et al.",
        "journal": "Alternatives to laboratory animals : ATLA",
        "date": "2026 Apr 9",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41954264/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41953965",
        "title": "Preclinical circulating tumor DNA shedding duration and prognostic implications of modeling 3669 patients with cancer in the American Cancer Society Cancer Prevention Study-3 and Circulating Cell-Free Genome Atlas Substudy 3.",
        "authors": "Hubbell E et al.",
        "journal": "Cancer",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41953965/",
        "sentiment": {
          "label": "negative",
          "score": -0.95,
          "confidence": 0.95
        }
      },
      {
        "source": "pubmed",
        "pmid": "41953607",
        "title": "First-principles investigation and device simulation of TlPbI(3)-based perovskite solar cells with machine learning-driven efficiency prediction.",
        "authors": "Harun-Or-Rashid M et al.",
        "journal": "RSC advances",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41953607/",
        "sentiment": {
          "label": "positive",
          "score": 0.161,
          "confidence": 0.16
        }
      },
      {
        "source": "pubmed",
        "pmid": "41951905",
        "title": "Towards noninvasive blood count using a deep learning pipeline from bulbar conjunctiva videos.",
        "authors": "Denis T et al.",
        "journal": "NPJ digital medicine",
        "date": "2026 Apr 8",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41951905/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41951647",
        "title": "Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trial.",
        "authors": "Matikas A et al.",
        "journal": "Nature communications",
        "date": "2026 Apr 8",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41951647/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41950571",
        "title": "Rational adjustment of dose to reduce adverse reactions (RADAR) in patients with platinum-sensitive recurrent ovarian cancer: Results from the phase II NEWTON trial (ENGOT-ov49).",
        "authors": "Colombo N et al.",
        "journal": "European journal of cancer (Oxford, England : 1990)",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41950571/",
        "sentiment": {
          "label": "negative",
          "score": -0.784,
          "confidence": 0.78
        }
      },
      {
        "source": "pubmed",
        "pmid": "41950362",
        "title": "Genomic Prostate Score (GPS) as a Prognostic Biomarker in Patients With Localized Prostate Cancer Undergoing Focal Therapy.",
        "authors": "Deivasigamani S et al.",
        "journal": "The Prostate",
        "date": "2026 Apr 8",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41950362/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41949867",
        "title": "Multimodal Assessment of Biological Age Following Radiation Therapy Among Patients With Early-Stage NSCLC.",
        "authors": "Lee G et al.",
        "journal": "JAMA network open",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41949867/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41948176",
        "title": "Mapping colorectal cancer screening workflows in primary care.",
        "authors": "Robertson EA et al.",
        "journal": "BMJ public health",
        "date": "2026-04-15",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41948176/",
        "sentiment": {
          "label": "negative",
          "score": -0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "pubmed",
        "pmid": "41947371",
        "title": "Prenatal Exome Diagnostic Yield, Syndromic Landscape and Secondary Findings.",
        "authors": "Avello K et al.",
        "journal": "Molecular genetics & genomic medicine",
        "date": "2026-04-15",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41947371/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41946804",
        "title": "LC-MS-based metabolomic characterization and POM pharmacophore analysis of the bioactive methanolic extract of Ephedra alata.",
        "authors": "Elsharkawy ER et al.",
        "journal": "Scientific reports",
        "date": "2026 Apr 7",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41946804/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41946470",
        "title": "Prevalence and characteristics of sessile serrated lesions with dysplasia in Dutch fecal immunochemical test-positive screenees.",
        "authors": "van Roermund NS et al.",
        "journal": "Endoscopy",
        "date": "2026 Apr 7",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41946470/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41946052",
        "title": "Geochemical assessment of potentially toxic elements in river sediments from a highly contaminated mining area - Cavnic, Romania.",
        "authors": "Lupu A et al.",
        "journal": "Marine pollution bulletin",
        "date": "2026 Apr 6",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41946052/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41945293",
        "title": "Non-Titanised Compared to Titanised Polypropylene Meshes Induce a Pro-Inflammatory and Anti-Angiogenic Response in Fibroblast Co-Cultures.",
        "authors": "Protsepko O et al.",
        "journal": "Cell biochemistry and biophysics",
        "date": "2026 Apr 7",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41945293/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41944925",
        "title": "Kluyveromyces marxianus CIDCA 9121 as Probiotic Supplement for Sows and Piglets: Effects on Biological and Productive Outcomes During Early Post-weaning.",
        "authors": "Pendón MD et al.",
        "journal": "Probiotics and antimicrobial proteins",
        "date": "2026 Apr 7",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41944925/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41942914",
        "title": "Social needs screening in hepatology clinic: a qualitative study of patient experience.",
        "authors": "Kim RG et al.",
        "journal": "BMC gastroenterology",
        "date": "2026 Apr 7",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41942914/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41941938",
        "title": "Radiation therapy management in BRCA1/2 carriers diagnosed with early breast cancer: An international cohort study.",
        "authors": "Becherini C et al.",
        "journal": "Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology",
        "date": "2026 Apr 4",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41941938/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41941058",
        "title": "Assessment of early return to drinking in surviving patients with alcohol-associated hepatitis.",
        "authors": "Cotter TG et al.",
        "journal": "Alcohol, clinical & experimental research",
        "date": "2026-04-15",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41941058/",
        "sentiment": {
          "label": "positive",
          "score": 0.296,
          "confidence": 0.3
        }
      },
      {
        "source": "pubmed",
        "pmid": "41935709",
        "title": "Learning to breathe for radiation therapy: A scoping review of deep inspiration breath-hold training.",
        "authors": "Lastrucci A et al.",
        "journal": "Critical reviews in oncology/hematology",
        "date": "2026 Apr 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41935709/",
        "sentiment": {
          "label": "positive",
          "score": 0.527,
          "confidence": 0.53
        }
      },
      {
        "source": "pubmed",
        "pmid": "41935304",
        "title": "From healing landscapes to biocultural conservation: the role of Ficus septica in karst ecosystems of South Sulawesi, Indonesia.",
        "authors": "Ismail A et al.",
        "journal": "Journal of ethnobiology and ethnomedicine",
        "date": "2026 Apr 4",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41935304/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "pubmed",
        "pmid": "41934720",
        "title": "Optimizing axillary lymph node management in early-stage HR+/HER2- breast cancer: Practical strategies for enhanced detection rates.",
        "authors": "Thill M et al.",
        "journal": "Breast (Edinburgh, Scotland)",
        "date": "2026 Mar 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41934720/",
        "sentiment": {
          "label": "negative",
          "score": -0.34,
          "confidence": 0.34
        }
      },
      {
        "source": "pubmed",
        "pmid": "41933521",
        "title": "Mind-wandering facilitates creative performance in a musical improvisation task.",
        "authors": "Palhares PT et al.",
        "journal": "Consciousness and cognition",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41933521/",
        "sentiment": {
          "label": "positive",
          "score": 0.44,
          "confidence": 0.44
        }
      },
      {
        "source": "pubmed",
        "pmid": "41932199",
        "title": "Plasma Hepcidin as a Prognostic Biomarker in Obese and Nonobese Patients With Early Breast Cancer: A Pooled Analysis of Two Prospective Cohort Studies.",
        "authors": "Cescon E et al.",
        "journal": "Clinical breast cancer",
        "date": "2026 Apr 2",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41932199/",
        "sentiment": {
          "label": "negative",
          "score": -0.66,
          "confidence": 0.66
        }
      },
      {
        "source": "pubmed",
        "pmid": "41931881",
        "title": "Effect of folic acid supplemented feed on metabolic and redox balance, and sperm movement in silver catfish (Rhamdia quelen) males.",
        "authors": "Baumgartner LA et al.",
        "journal": "Theriogenology",
        "date": "2026 Apr 1",
        "url": "https://pubmed.ncbi.nlm.nih.gov/41931881/",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "sec",
        "filing_type": "8-K",
        "title": "8-K  - Current report",
        "date": "2026-03-23",
        "url": "https://www.sec.gov/Archives/edgar/data/1124140/000119312526118700/0001193125-26-118700-index.htm",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      },
      {
        "source": "sec",
        "filing_type": "8-K",
        "title": "8-K  - Current report",
        "date": "2026-03-20",
        "url": "https://www.sec.gov/Archives/edgar/data/1124140/000119312526116862/0001193125-26-116862-index.htm",
        "sentiment": {
          "label": "neutral",
          "score": 0.0,
          "confidence": 0.0
        }
      }
    ]
  }
}